Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice

被引：0
|
作者：
Mansilla-Polo, Miguel [1 ,2 ]
Sahuquillo-Torralba, Antonio [1 ,2 ]
Pujol-Marco, Conrad [1 ,2 ]
Bargues-Navarro, Guillermo [1 ,2 ]
Botella-Estrada, Rafael [1 ,2 ,3 ]
机构：
[1] Hosp Univ & Politecn La Fe, Dept Dermatol, Valencia, Spain
[2] Inst Invest Sanitaria La Fe IIS La Fe, Dept Dermatol, Valencia, Spain
[3] Univ Valencia, Fac Med, Dept Dermatol, Valencia, Spain
来源：
ANAIS BRASILEIROS DE DERMATOLOGIA | 2024年 / 99卷 / 06期
关键词：
D O I：
10.1016/j.abd.2024.04.004
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：922 / 927
页数：6
相关论文
共 50 条
  • [41] REAL-WORLD EFFECTIVENESS AND SAFETY IN A PHASE 4 STUDY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Bhatia, N.
    Vasquez, J. G.
    Schenkel, B.
    Rozzo, S. J.
    Heim, J.
    VALUE IN HEALTH, 2023, 26 (06) : S57 - S57
  • [42] AIRIS-Crohn: Results on the Effectiveness and Safety of Risankizumab in the Medium Term in Real-World Clinical Practice
    Mateos, A. M. Caballero
    Martin, R. V. Olmedo
    Gijon-Villanova, R.
    Gutierrez-Holanda, C.
    Fernandez-Moreno, N.
    Martin-Rodriguez, M. D. M.
    Silva-Albarellos, E.
    Rodriguez-Gonzalez, F. J.
    Hernandez-Martinez, A.
    Benitez, J. M.
    Mata, F. J.
    Trapero-Martinez, A. M.
    Valdes-Delgado, T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1568 - i1570
  • [43] Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study
    Marschner, Norbert
    Haug, Nina
    Hegewisch-Becker, Susanna
    Reiser, Marcel
    Doerfel, Steffen
    Lerchenmueller, Christian
    Linde, Hartmut
    Wolf, Thomas
    Hof, Anna
    Kaiser-Osterhues, Anja
    Potthoff, Karin
    Jaenicke, Martina
    INTERNATIONAL JOURNAL OF CANCER, 2024,
  • [44] A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 12-Week Efficacy, Safety, and Speed of Response from a Randomized, Double-Blinded Trial
    Blauvelt, Andrew
    Papp, Kim
    Jarell, Abel
    Reich, Kristian
    Gottlieb, Alice
    Lima, Renata Gontijo
    Elmaraghy, Hany
    Gallo, Gaia
    Renda, Lisa
    Park, So Young
    Bagel, Jerry
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 16 - 17
  • [45] A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial
    Blauvelt, A.
    Leonardi, C.
    Elewski, B.
    Crowley, J. J.
    Guenther, L. C.
    Gooderham, M.
    Langley, R. G.
    Vender, R.
    Pinter, A.
    Griffiths, C. E. M.
    Tada, Y.
    Elmaraghy, H.
    Lima, R. G.
    Gallo, G.
    Renda, L.
    Burge, R.
    Park, S. Y.
    Zhu, B.
    Papp, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (06) : 1047 - 1058
  • [46] Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
    Megna, Matteo
    Ruggiero, Angelo
    Tommasino, Nello
    Brescia, Claudio
    Martora, Fabrizio
    Cacciapuoti, Sara
    Potestio, Luca
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2024, 17 : 1037 - 1042
  • [47] A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
    Blauvelt, A.
    Papp, K.
    Gottlieb, A.
    Jarell, A.
    Reich, K.
    Maari, C.
    Gordon, K. B.
    Ferris, L. K.
    Langley, R. G.
    Tada, Y.
    Lima, R. G.
    Elmaraghy, H.
    Gallo, G.
    Renda, L.
    Park, S. Y.
    Burge, R.
    Bagel, J.
    Devani, Alim
    Vender, Ronald
    Lomaga, Mark A.
    Delorme, Isabelle
    Hong, Chih-Ho
    Langley, Richard L.
    Albrecht, Lorne
    Guenther, Lyn
    Maari, Catherine
    Papp, Kim
    Ohson, Kamal K. Singh
    Barber, Kirk
    Lynde, Charles
    Gupta, Aditya
    Rosoph, Leslie
    Gauthier, Jean-Sebastien
    Gooderham, Melinda
    Wasel, Norman
    Raman, Mani
    Wiseman, Marni
    Greenstein, David
    Jarell, Abel
    Moon, Charles
    Clark, Lani
    Jazayeri, Sadra Sasha
    Bukhalo, Michael
    Moore, Angela
    Hamilton, Tiffani K.
    Gewirtzman, Aron
    Hazan, Lydie
    Crowley, Jeffrey
    Teller, Craig
    Zirwas, Matthew
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (06) : 1348 - 1358
  • [48] Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study
    Ruiz-Villaverde, R.
    Galan-Gutierrez, M.
    Armario-Hita, J. C.
    Rodriguez-Fernandez-Freire, L.
    ACTAS DERMO-SIFILIOGRAFICAS, 2024, 115 (03): : T321 - T323
  • [49] Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT
    Tsianakas, Athanasios
    Schwichtenberg, Uwe
    Pierchalla, Peter
    Hinz, Torsten
    Diemert, Sebastian
    Korge, Bernhard
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (01) : 85 - 92
  • [50] Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
    Sakai, Ryoko
    Cho, Soo-Kyung
    Nanki, Toshihiro
    Watanabe, Kaori
    Yamazaki, Hayato
    Tanaka, Michi
    Koike, Ryuji
    Tanaka, Yoshiya
    Saito, Kazuyoshi
    Hirata, Shintaro
    Amano, Koichi
    Nagasawa, Hayato
    Sumida, Takayuki
    Hayashi, Taichi
    Sugihara, Takahiko
    Dobashi, Hiroaki
    Yasuda, Shinsuke
    Sawada, Tetsuji
    Ezawa, Kazuhiko
    Ueda, Atsuhisa
    Fujii, Takao
    Migita, Kiyoshi
    Miyasaka, Nobuyuki
    Harigai, Masayoshi
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
12345